April 15, 2020: New York, NY
New Drug Delivery Platform and Immunotherapeutic Compositions Against Cancer Using Proprietary Microchannel Technology - Aquavit Pharmaceuticals, Inc. Announces New Patent Application Filing
New York-based Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, today announced that the company has filed a new patent application with the United States Patent and Trademark Office. The patent application covers methods for inducing immune responses and treating cancer by administering immunotherapeutic compositions to a patient’s skin using Aquavit’s microchannel delivery technology.
Aquavit recently filed patent applications for drug delivery platforms to immunize patients against pandemic outbreaks such as COVID-19 caused by the SARS-CoV-2 coronavirus, and the new filling directed to cancer therapy expands the applications of this unique technology platform. “Cancer immunotherapies are advancing at a rapid pace and Aquavit’s proprietary microchannel delivery technology provides a platform to precisely deliver therapeutic vaccines to the epidermal and dermal skin layers, areas that are rich in antigen-presenting cells,” says Dr. Daniel Nevrivy Ph.D., J.D., Aquavit’s Scientific Advisor.
Aquavit’s microchannel technology overcomes the existing problems of vaccine delivery while also avoiding bleeding and pain that are normally associated with commercially available immunization methods. A related technology is currently used in Aquavit’s highly acclaimed AQUAGOLD® fine touch™ (www.aquagold finetouch.com) device. AQUAGOLD® is currently used by many medical professionals to micro-inject drugs and biologics into the dermal and epidermal skin layers for dermatological applications.
“It has been an exciting phase at Aquavit as we are actively working to bring these new technologies to the market as soon as possible. We believe our technologies can modernize how we deliver drugs and pave the way for personalized healthcare” says Sobin Chang, MPH, Chief Executive Officer of Aquavit and a Board Director of Association of Yale Alumni in Public Health.
Aquavit’s IP portfolio covers four major areas including smart compounding technology, dermatology, vaccine administration, and skin cancer.
About Aquavit Pharmaceuticals, Inc. Aquavit Pharmaceuticals, Inc., located in New York City, is developing several innovative products and platform technology IP for personalized medicine. Aquavit’s major innovation is a patented micro-channel® technology - a novel route of administration (RoA) for drugs and biologics. Micro-channel® technology allows for inter-dermal delivery, which has higher efficacy and speed of delivery for any drug or therapeutic agent currently delivered either topically or via a patch form. Application for microchannel technology® range from medical aesthetics, dermatology, infectious diseases to oncology. The company’s mission is to modernize and personalize healthcare for patients through innovative drug and biologics delivery systems.
Additional information about Aquavit can be found at www.aquavitpharma.com.
Forward-Looking Statements To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting device approvals, acceptance and demand for new products, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Media Contact: Meghan Burke, Corporate Communications 212.253.0523 email@example.com